title: Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
abstract: In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed. Among these, immunotherapy offers a series of advantages such as tumor specificity and good tolerability. Unfortunately, MPM immunotherapy is frequently limited by incomplete cell differentiation or feedback loop regulatory mechanisms. In this review, we describe different components of the innate immune system and discuss strategies to improve MPM immunotherapy by using epigenetic modulators.
authors: Malik
authors: M
authors: Hamaidia
authors: Bernard
authors: B
authors: Staumont
authors: Bernard
authors: B
authors: Duysinx
authors: Renaud
authors: R
authors: Louis
authors: Department of AgroBioChem, University of Liege, 5030, Gembloux, Belgium. luc.willems@ulg.ac.be.
authors: Luc
authors: L
authors: Willems
mesh_terms: D000818:Animals; D044127:Epigenesis, Genetic / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008654:Mesothelioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000086002:Mesothelioma, Malignant
chemical_list: D056572:Histone Deacetylase Inhibitors